South Korea · Delayed Price · Currency is KRW Oncocross Statistics
Total Valuation
Oncocross has a market cap or net worth of KRW 57.32 billion. The enterprise value is 38.47 billion.
| Market Cap | 57.32B |
| Enterprise Value | 38.47B |
Important Dates
The next estimated earnings date is Thursday, August 13, 2026.
| Earnings Date | Aug 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Oncocross has 12.20 million shares outstanding. The number of shares has increased by 10.92% in one year.
| Current Share Class | 12.20M |
| Shares Outstanding | 12.20M |
| Shares Change (YoY) | +10.92% |
| Shares Change (QoQ) | +0.96% |
| Owned by Insiders (%) | 25.25% |
| Owned by Institutions (%) | 10.87% |
| Float | 6.97M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 120.64 |
| PB Ratio | 4.90 |
| P/TBV Ratio | 4.92 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 80.97 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.75, with a Debt / Equity ratio of 0.72.
| Current Ratio | 3.75 |
| Quick Ratio | 3.69 |
| Debt / Equity | 0.72 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.97 |
| Interest Coverage | -10.19 |
Financial Efficiency
Return on equity (ROE) is -61.99% and return on invested capital (ROIC) is -28.80%.
| Return on Equity (ROE) | -61.99% |
| Return on Assets (ROA) | -20.68% |
| Return on Invested Capital (ROIC) | -28.80% |
| Return on Capital Employed (ROCE) | -33.00% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.02 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -65.59% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -65.59% |
| 50-Day Moving Average | 7,235.10 |
| 200-Day Moving Average | 8,828.73 |
| Relative Strength Index (RSI) | 25.94 |
| Average Volume (20 Days) | 86,414 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Oncocross had revenue of KRW 475.15 million and -9.31 billion in losses. Loss per share was -774.05.
| Revenue | 475.15M |
| Gross Profit | 439.58M |
| Operating Income | -8.96B |
| Pretax Income | -9.31B |
| Net Income | -9.31B |
| EBITDA | -8.00B |
| EBIT | -8.96B |
| Loss Per Share | -774.05 |
Balance Sheet
The company has 27.25 billion in cash and 8.40 billion in debt, with a net cash position of 18.85 billion or 1,545.52 per share.
| Cash & Cash Equivalents | 27.25B |
| Total Debt | 8.40B |
| Net Cash | 18.85B |
| Net Cash Per Share | 1,545.52 |
| Equity (Book Value) | 11.70B |
| Book Value Per Share | 963.91 |
| Working Capital | 20.64B |
Cash Flow
In the last 12 months, operating cash flow was -6.27 billion and capital expenditures -2.38 billion, giving a free cash flow of -8.65 billion.
| Operating Cash Flow | -6.27B |
| Capital Expenditures | -2.38B |
| Depreciation & Amortization | 951.96M |
| Net Borrowing | 19.17B |
| Free Cash Flow | -8.65B |
| FCF Per Share | -709.23 |
Margins
| Gross Margin | 92.51% |
| Operating Margin | -1,884.98% |
| Pretax Margin | -1,959.09% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Oncocross does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -10.92% |
| Shareholder Yield | -10.92% |
| Earnings Yield | -16.24% |
| FCF Yield | -15.09% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Oncocross has an Altman Z-Score of 0.63 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.63 |
| Piotroski F-Score | 1 |